UE LifeSciences, with a valuation of $50 million, is raising funds independently through Reg D 506(c) crowdfunding. The company has developed non-invasive and radiation-free devices and apps for the detection of breast and cervical cancer. The technology of UE LifeSciences is US FDA cleared, CE marked, and clinically validated by multiple independent studies. UE LifeSciences has successfully pre-screened over 450,000 women and has been featured in the New York Times, Forbes, BBC, and Vogue. Mihir Shah and Matthew Campisi founded UE LifeSciences in 2003. The current crowdfunding campaign has a minimum target of $5,000 and a maximum target of $5,000,000. The campaign proceeds will be used for growth and expansion.